Selective p38 MAPK Inhibitors for Chronic Lung Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p38 MAP kinase inhibitors face challenges due to toxicity and limited therapeutic potential, particularly for treating chronic inflammatory diseases like COPD, where they are often corticosteroid-insensitive and have short durations of action.
Innovation Solution
Development of specific compounds, such as those represented by formula (I), which are potent inhibitors of p38 MAPK enzymes with selectivity for the p38-alpha isoform over p38-gamma, offering extended therapeutic action and reduced toxicity, suitable for topical administration to the lung.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pan-isoform p38 MAPK inhibitors are used, then broad inhibitory activity is achieved, but toxicity increases due to ubiquitous expression of p38 alpha and beta isoforms
Solution Approach 1:
The patent applies local quality by designing inhibitors with selective affinity for specific p38 isoforms (gamma and delta) rather than uniformly inhibiting all isoforms. The compounds are engineered to target tissues where p38 gamma and delta are specifically expressed (brain, skeletal muscle, heart, lymphocytes, macrophages) while sparing tissues where p38 alpha and beta are ubiquitously expressed, thereby achieving localized therapeutic effect with reduced systemic toxicity.
2Reliability
If corticosteroid treatment is used for COPD, then anti-inflammatory effects are achieved, but corticosteroid insensitivity develops
Solution Approach 1:
The patent applies inversion by switching from the conventional approach of using corticosteroids to inhibit p38 alpha/beta pathways to using p38 gamma/delta selective inhibitors that target alternative inflammatory pathways. This inverse strategy bypasses the corticosteroid insensitivity problem by engaging a different mechanistic pathway for achieving anti-inflammatory effects in corticosteroid-resistant COPD patients.
3Reliability
If existing p38 MAPK inhibitors are used, then inflammatory parameters are reduced, but duration of action is short
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure and pharmacokinetic properties of the inhibitor compounds to achieve longer residence times in the lung. The compounds are designed with specific molecular characteristics that enhance their binding affinity and retention in pulmonary tissues, thereby extending the duration of anti-inflammatory action beyond that of previous generations of p38 MAPK inhibitors.
Data Source
AI summary
There is provided inter alia a compound of formula (I):wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.